Theriva Biologics, Inc. Operating Income Loss

• Theriva Biologics, Inc. showed an increase of +8.7% in Operating Income Loss from 2024 to 2025.
• This data is from Theriva Biologics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Theriva Biologics, Inc.'s Operating Income Loss has declined by 39.0%.
• Historical annual values: Fiscal year 2025: -$24.05 million | Fiscal year 2024: -$26.35 million | Fiscal year 2023: -$21.43 million | Fiscal year 2022: -$21.58 million | Fiscal year 2021: -$14.27 million | Fiscal year 2020: -$10.16 million | Fiscal year 2019: -$15.66 million | Fiscal year 2018: -$17.57 million | Fiscal year 2017: -$26.25 million | Fiscal year 2016: -$39.25 million | Fiscal year 2015: -$40.98 million | Fiscal year 2014: -$20.50 million | Fiscal year 2013: -$12.34 million | Fiscal year 2012: -$17.30 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026